73 completed, 16 terminated, 7 recruiting, 4 active not recruiting. 58 Phase 1, 49 Phase 2, 8 Not applicable, 3 Early Phase 1, 1 Phase 3.
Follow Anaplastic Large Cell Lymphoma: new trials by email Literature Review of Anaplastic Large Cell Lymphoma trials Research Report on Anaplastic Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BV-CHP Real-life and Biological Evidences in Patients With sALCL Anaplastic Large Cell Lymphoma | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 100 | 2026-09-01 | 2026-09-09 | |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma azacitidine, abatacept - Lymphoma, T Cell, Peripheral, T-cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-03-26 | 2026-10-20 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) Alectinib, Duvelisib - Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2025-08-08 | 2026-05-26 |
| A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma LCAR-HL30 cells - Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Recruiting | Ruijin Hospital | 32 | 2024-07-01 | 2024-07-10 |
| Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | Mayo Clinic | 21 | 2024-01-05 | 2026-07-01 |
| DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers Alectinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-12-18 | 2025-11-24 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types No interventions need to be specified for this study - Lymphoma, Extranodal Lymphoma | Unknown | Ruijin Hospital | 10000 | 2023-07-01 | 2023-06-18 | |
| Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies anti-CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 14 | 2022-05-04 | 2025-06-06 |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma Anti CD30 CAR-T Cell Injection - Hodgkin Lymphoma, NK/T Cell Lymphoma | Early Phase 1 | Unknown | Zhejiang University | 9 | 2022-02-10 | 2022-01-26 |
| Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma CD30.CAR-T - Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma | Phase 1 | Active not recruiting | Tessa Therapeutics | 21 | 2021-09-08 | 2023-04-20 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma brentuximab vedotin - Hodgkin Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Terminated | Seagen Inc. | 12 | 2019-10-28 | 2023-10-13 |
| Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Anti-CD30 CAR T cells - Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma | Phase 1 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 50 | 2019-07-03 | 2019-08-07 |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies rhIL-15, Avelumab - Peripheral T-cell Lymphoma NOS, Mycosis Fungoides | Phase 1 | Completed | National Cancer Institute (NCI) | 8 | 2019-06-07 | 2022-09-13 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma AUTO4 - T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Terminated | Autolus Limited | 20 | 2018-08-30 | 2026-03-16 |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma Laboratory Biomarker Analysis, Romidepsin, Venetoclax - Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 12 | 2018-08-21 | 2023-10-19 |
Showing 20 of 112. Sign in to see all of them.
Lymphoma, Large-Cell, Anaplastic (112) · Immunoblastic Lymphadenopathy (78) · Lymphoma, Large B-Cell, Diffuse (74) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (70) · Lymphoma, Follicular (67) · Lymphoma, Mantle-Cell (67) · Mycosis Fungoides (66) · Lymphoma, B-Cell, Marginal Zone (65) · Sezary Syndrome (64) · Burkitt Lymphoma (63) · Hodgkin Disease (63) · Lymphoma, T-Cell, Cutaneous (62) · Leukemia, Lymphocytic, Chronic, B-Cell (61) · Lymphoma, Non-Hodgkin (61) · Lymphoma, Extranodal NK-T-Cell (59)
Hemic and Lymphatic Diseases (112) · Immune System Diseases (111) · Immunoproliferative Disorders (111) · Lymphatic Diseases (111) · Lymphoproliferative Disorders (110) · Neoplasms (110) · Neoplasms by Histologic Type (110) · Lymphoma (104) · Lymphoma, T-Cell (90) · Hematologic Diseases (80) · Lymphadenopathy (78) · Leukemia, Lymphoid (77) · Lymphoma, B-Cell (77) · Leukemia (74) · Pathologic Processes (67)
Peripheral Blood Stem Cell Transplantation (15) · Whole-Body Irradiation (14) · fludarabine phosphate (14) · Mycophenolic Acid (13) · Cyclophosphamide (11) · Cyclosporine (11) · Etoposide (9) · Rituximab (8) · Brentuximab Vedotin (6) · Lenalidomide (6) · tanespimycin (5) · Bendamustine Hydrochloride (4) · Bortezomib (4) · Flow Cytometry (4) · Gene Expression Profiling (4)
National Cancer Institute (NCI) (35) · Fred Hutchinson Cancer Center (17) · City of Hope Medical Center (6) · Mayo Clinic (6) · Case Comprehensive Cancer Center (4) · Children's Cancer Group, China (2) · Northwestern University (2) · Roswell Park Cancer Institute (2) · Ruijin Hospital (2) · University of Nebraska (2) · University of Washington (2) · Wake Forest University Health Sciences (2) · AIDS Malignancy Consortium (1) · Amir Mortazavi (1) · Autolus Limited (1)
United States (96) · Italy (10) · China (9) · Canada (5) · Germany (3) · France (2) · Spain (2) · United Kingdom (2) · Czechia (1) · Denmark (1) · Israel (1) · South Korea (1) · Taiwan (1) · Thailand (1)
Ajay Gopal (4) · David Maloney (4) · Brenda Sandmaier (3) · Ryotaro Nakamura (3) · Ann Woolfrey (2) · George Chen (2) · Julie M Vose (2) · Ramesh Ramanathan (2) · Samuel Y Ng, M.D. (2) · Yijin Gao, MD (2) · Adam Petrich, MD (1) · Alex F Herrera (1) · Alexandra M. Levine, MD (1) · Alison Stopeck (1) · Amir Mortazavi, MD (1)
PMID 32499241, PMID 18698002, PMID 19900571, PMID 21725056, PMID 22259028, PMID 23256542, PMID 24241210, PMID 24352795, PMID 24474568, PMID 26077240, PMID 26213141, PMID 26764356, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28314788, PMID 28869931, PMID 29276022, PMID 29292843, PMID 30562587, PMID 31617432, PMID 32508818, PMID 33492438, PMID 33883258, PMID 34515338, PMID 35175355, PMID 37276067, PMID 37327113, PMID 39528665
P30CA015704 (12), P01CA018029 (4), P30CA015083 (4), U01CA062491 (4), U01CA076576 (4), U01CA099168 (4), N01CM62202 (3), P30CA016058 (3), P30CA016672 (3), U01CA062487 (3), U01CA062505 (3), U10CA032102 (3), 2017 (2), P01CA044991 (2), P01CA078902 (2)